India Pharma Outlook Team | Friday, 22 August 2025
In a revolutionary stride that will change the landscape of cancer diagnostics in India, Dr. Lal PathLabs (DLPL) has become the first laboratory in the country to implement a deep learning based AI module for the identification of lymph node metastasis, even identifying micrometastasis, in cancer cases.
When the product was exhibited at USCAP 2023, an international conference for pathology, it was a state-of-the-art product validated with Qritive. Determining the stage and course of treatment for patients depends on accurately identifying cancer that has progressed to lymph nodes.
Cancer can advance to later stages if the lymph node spread is not recognized, which raises the possibility of metastasis to other organs and drastically lowers survival rates. As a result, the discovery of concealed metastases in patients with early-stage cancer may significantly influence treatment planning and the best course of action for cancer patients.
Detecting micrometastases-small clusters of cancer cells in lymph nodes-usually takes a long time and requires special tests. QiAI Lymph Node Dx uses the power of deep learning to quickly and accurately detects cancer cells on digital slides, and by incorporating this technology into routine practice will make cancer diagnoses quicker and more accurate.
Also Read: TrioTree Technologies Launches AI-Powered Voice-to-Structured-Data System
"At Dr. Lal PathLabs, we are proud to lead the way in bringing AI diagnostics to India," said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs. "This advanced technology allows us to identify cancer spread with exceptional precision and speed - particularly micrometastasis that may be missed by the human eye. By integrating AI into our pathology workflow, we are not only enhancing diagnostic accuracy but also enabling quicker clinical decisions, which can significantly improve treatment outcomes and quality of life for patients."
